Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 12/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | CFTR | P13569 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | TLR2 | O60603 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234573 | 0.88 | FLT3 (0.72) | FLT3MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL5462791 | 0.87 | FLT3 (0.72) | FLT3MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL18015730 | 0.86 | KCNH2 (0.71) | FLT3MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL5451319 | 0.86 | KCNH2 (0.52) | FLT3MAPTMEN1KMT2ACYP2C19 | |
| SCHEMBL5453610 | 0.85 | FLT3 (0.77) | FLT3MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL14136793 | 0.85 | FLT3 (0.52) | FLT3MAPTMEN1KMT2ACYP2C19 | |
| SCHEMBL5446006 | 0.85 | CFTR (0.61) | FLT3MAPTMEN1KMT2ANPC1 | |
| SCHEMBL5455065 | 0.85 | MEN1 (0.79) | FLT3MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL5467902 | 0.85 | FLT3 (0.72) | FLT3MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL5450860 | 0.84 | MEN1 (0.78) | FLT3MAPTMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | FLT3 3509/4885MAPT 21/4885MEN1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.